Skip to main content

Table 3 Clinical trials with immune checkpoints therapy in liver cancers

From: Immune checkpoint therapy in liver cancer

Cancer type

Number

Study arms

Stage

Status

Design

Primary outcome

Estimated completion

Trial NCT

HCC

35

Nivolumab (anti PD-1 Ab) + LRT (Yttrium 90Y glass microspheres)

Phase 1

Recruiting

Single Group Assignment

July 2019

July 2019

NCT02837029

HCC

154

PDR001 (anti PD-1 Ab) + NIS793 (anti TGF-b Ab)

Phase 1

Recruiting

Non-Randomized

January 12, 2020

January 12, 2020

NCT02947165

HCC

114

Durvalumab (anti PD-1L Ab) + ramucirumab (anti-VEGF-R2 Ab)

Phase 1

Recruiting

Non-Randomized

March 2018

September 2018

NCT02572687

HCC

51

Durvalumab (anti PD-1 L Ab) + AZD4635

Phase 1

Recruiting

Non-Randomized

November 9, 2017

November 9, 2017

NCT02740985

HCC

61

Tremelimumab (anti CTLA-4 Ab)

Phase 1

Active, not recruiting

Non-Randomized

December 31, 2017

December 31, 2018

NCT01853618

Liver cancer

60

Ipilimumab (anti CTLA-4 Ab) + MGN1703 (Toll-like receptor agonist)

Phase 1

Recruiting

Non-Randomized

May 2019

May 2019

NCT02668770

HCC

120

Ipilimumab (anti CTLA-4 Ab) + stereotactic body radiation

Phase 1

Recruiting

Randomized

August 2019

August 2019

NCT02239900

HCC

75

Nivolumab (anti PD-1 Ab) + galunisertib (TGF-b inhibitor)

Phase 1/2

Recruiting

Non-Randomized

April 2018

March 2019

NCT02423343

HCC

620

Nivolumab (anti PD-1 Ab) + ipilimumab (anti CTLA-4 Ab)

Phase 1/2

Recruiting

Non-Randomized

July 22, 2018

July 9, 2019

NCT01658878

HCC

108

PDR001 (anti PD-1 Ab) + INC280 (c-Met inhibitor)

Phase 1/2

Recruiting

Non-Randomized

December 24, 2018

December 24, 2018

NCT02795429

HCC

50

Prembrolizumab (anti PD-1 Ab) + dendritic cells, cytokine-induced killer cells

Phase 1/2

Recruiting

Single Group Assignment

September 2019

October 2019

NCT02886897

HCC

15

Prembrolizumab (anti PD-1 Ab)

Phase 1/2

Recruiting

Single Group Assignment

December 2019

December 2019

NCT02940496

HCC

50

Nivolumab (anti PD-1 Ab) + CC-122 (immunostimulatory pathway modifier)

Phase 1/2

Recruiting

Single Group Assignment

June 23, 2020

June 23, 2020

NCT02859324

HCC

90

Durvalumab (anti PD-1 L Ab), Tremelimumab (anti CTLA-4 Ab) + LRT

Phase 1/2

Recruiting

Non-Randomized

April 30, 2020

April 30, 2021

NCT02821754

HCC

620

Nivolumab (anti PD-1 Ab), Nivolumab + Ipilimumab, Nivolumab + cabozantinib, Nivolumab + Ipilimumab + cabozantinib

Phase 1/2

Recruiting

Non- Randomized

September 4, 2018

July 9, 2019

NCT01658878

HCC

28

Pembrolizumab (Keytruda) (anti PD-1 Ab)

Phase 2

Recruiting

Single Group Assignment

April 2018

April 2019

NCT02658019

HCC

440

Durvalumab (anti PD-1 L Ab) + Tremelimumab (anti CTLA-4 Ab)

Phase 2

Recruiting

Randomized

March 20, 2020

March 20, 2020

NCT02519348

HCC

726

Nivolumab (anti PD-1 Ab)

Phase 3

Recruiting

Randomized

October 1, 2018

June 22, 2019

NCT02576509

HCC

408

Prembrolizumab (anti PD-1 Ab)

Phase 3

Active, not recruiting

Randomized

February 1, 2019

February 1, 2019

NCT02702401

HCC

1200

Durvalumab (anti PD-1 L Ab) + tremelimumab (anti CTLA-4 Ab)

Phase 3

Not yet recruiting

Randomized

February 27, 2020

March 29, 2021

NCT03298451